UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

NCT00146042 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

HER-2 Positive Metastatic Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Trastuzumab
PROCEDURE: Erythromycin Breath Test (ERMBT)

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]